Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong
Go back to Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 212.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $212.50 | 52 Week High | $333.65 | |||
| Open | $212.50 | 52 Week Low | $223.02 | |||
| Day High | $212.50 | P/E | 27.21 | |||
| Day Low | $212.50 | EPS | $7.81 | |||
| Volume | 155 | |||||
| (NASDAQ: STOK) | Delayed: 30.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.05 | 52 Week High | $ | |||
| Open | $30.05 | 52 Week Low | $ | |||
| Day High | $30.05 | P/E | N/A | |||
| Day Low | $30.05 | EPS | $ | |||
| Volume | 6,349 | |||||
